Affordable Access

deepdyve-link
Publisher Website

Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.

Authors
  • Svahn, Thommy1
  • Mellgren, Karin1
  • Harila-Saari, Arja2
  • Åsberg, Ann3
  • Kanerva, Jukka4
  • Jónsson, Ólafur5
  • Vaitkeviciene, Goda6
  • Stamm Mikkelssen, Torben7
  • Schmiegelow, Kjeld8
  • Heldrup, Jesper9
  • 1 Department of Pediatrics, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. , (Sweden)
  • 2 Department of Women's and Children's Health, Karolinska Institutet and Astrid Lindgren Children's Hospital, Karolinska Hospital, Stockholm, Sweden. , (Sweden)
  • 3 Pediatric Department, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway. , (Norway)
  • 4 Children's Hospital, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland. , (Finland)
  • 5 Children's Hospital, Landspítali University Hospital, Reykjavik, Iceland. , (Iceland)
  • 6 Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos and Vilnius University, Vilnius, Lithuania. , (Lithuania)
  • 7 Department of Pediatrics, Aarhus University, Denmark. , (Denmark)
  • 8 Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark. , (Denmark)
  • 9 Department of Pediatrics, Skåne University Hospital, Lund, Sweden. , (Sweden)
Type
Published Article
Journal
Pediatric Blood & Cancer
Publisher
Wiley (John Wiley & Sons)
Publication Date
Dec 14, 2016
Identifiers
DOI: 10.1002/pbc.26395
PMID: 27966809
Source
Medline
Keywords
License
Unknown

Abstract

CPDG2 administration is highly effective as rescue in case of delayed Mtx clearance. Subsequent HDMtx courses could be administered without events in most of the patients.

Report this publication

Statistics

Seen <100 times